Price T Rowe Associates Inc Denali Therapeutics Inc. Transaction History

Price T Rowe Associates Inc

  • $812 Billion
  • Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,367,234 shares of DNLI stock, worth $61.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,367,234
Previous 3,058,615 42.78%
Holding current value
$61.8 Million
Previous $62.3 Million 4.75%
% of portfolio
0.01%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
BUY
$13.6 - $23.59 $17.8 Million - $30.9 Million
1,308,619 Added 42.78%
4,367,234 $59.4 Million
Q4 2024

Feb 14, 2025
BUY
$20.24 - $31.58 $3.82 Million - $5.96 Million
188,820 Added 6.58%
3,058,615 $62.3 Million
Q3 2024

Nov 14, 2024
BUY
$20.96 - $31.05 $12.9 Million - $19.1 Million
614,325 Added 27.24%
2,869,795 $83.6 Million
Q2 2024

Aug 14, 2024
BUY
$14.96 - $23.22 $9.89 Million - $15.4 Million
661,137 Added 41.47%
2,255,470 $52.4 Million
Q1 2024

May 15, 2024
SELL
$15.83 - $23.35 $15.5 Million - $22.9 Million
-979,988 Reduced 38.07%
1,594,333 $32.7 Million
Q4 2023

Feb 14, 2024
SELL
$16.2 - $23.18 $5.15 Million - $7.36 Million
-317,629 Reduced 10.98%
2,574,321 $55.2 Million
Q3 2023

Nov 14, 2023
SELL
$20.63 - $30.17 $11.4 Million - $16.7 Million
-553,362 Reduced 16.06%
2,891,950 $59.7 Million
Q2 2023

Aug 14, 2023
SELL
$23.37 - $32.96 $2.16 Million - $3.05 Million
-92,466 Reduced 2.61%
3,445,312 $102 Million
Q1 2023

May 15, 2023
SELL
$21.91 - $32.67 $2.43 Million - $3.63 Million
-111,110 Reduced 3.05%
3,537,778 $81.5 Million
Q4 2022

Feb 14, 2023
BUY
$26.28 - $33.92 $4.48 Million - $5.78 Million
170,520 Added 4.9%
3,648,888 $101 Million
Q3 2022

Nov 14, 2022
SELL
$25.97 - $38.53 $29.4 Million - $43.6 Million
-1,131,809 Reduced 24.55%
3,478,368 $107 Million
Q2 2022

Aug 15, 2022
SELL
$20.88 - $35.19 $6.54 Million - $11 Million
-313,248 Reduced 6.36%
4,610,177 $136 Million
Q1 2022

May 16, 2022
BUY
$29.0 - $47.27 $8.35 Million - $13.6 Million
287,992 Added 6.21%
4,923,425 $158 Million
Q4 2021

Feb 14, 2022
SELL
$42.59 - $55.02 $5.22 Million - $6.74 Million
-122,532 Reduced 2.58%
4,635,433 $207 Million
Q3 2021

Nov 15, 2021
SELL
$48.48 - $78.23 $7.05 Million - $11.4 Million
-145,487 Reduced 2.97%
4,757,965 $240 Million
Q2 2021

Aug 16, 2021
SELL
$50.3 - $78.44 $58.1 Million - $90.6 Million
-1,154,827 Reduced 19.06%
4,903,452 $385 Million
Q1 2021

May 17, 2021
SELL
$53.8 - $81.53 $21.9 Million - $33.1 Million
-406,547 Reduced 6.29%
6,058,279 $346 Million
Q4 2020

Feb 16, 2021
BUY
$36.89 - $93.56 $238 Million - $605 Million
6,464,826 New
6,464,826 $541 Million

Others Institutions Holding DNLI

# of Institutions
234
Shares Held
124M
Call Options Held
37.3K
Put Options Held
7.9K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $1.9B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email